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Alchornea cordifolia, known as Pennah, has been used extensively as a medicinal plant in 
Africa for treating a variety of ailments. Crude water (H2O) and methanol (MeOH) extracts 
prepared from dried leaves of Pennah were tested for antiviral activity against Herpes simplex 
virus type 2 (HSV2) by plaque reduction assays, showing crude MeOH more effective as an 
antiviral against HSV2. Assays with fractionated MeOH extract resulted in highest plaque 
reduction in the 30% MeOH fraction (30% Pennah MeOH) at a significant 98% reduction at 250 
µg/mL. Crude and 30% Pennah MeOH were found to contain alkaloids, phenols, and terpenoids.  
Immunofluorescence technique was utilized to visualize the extent viral products were 
synthesized in infected Vero cells treated with 30% Pennah MeOH extract according to different 
times of infection. Indirect immunofluorescence assays used to observe the course of HSV2 
infection in the Vero cells in conjunction with time-sensitive and neutralization assays uncovered 
the extract did not prevent total viral attachment, but showed inhibition of viral replication. The 
specific step after viral attachment and penetration inhibited is still unknown, requiring further 
investigation. Time sensitive assays suggest extract must be in the presence of unattached viral 
particle to inhibit the viral replication due to decreased plaque reduction when extract is removed 
in comparison to applied to the cells at 2 and 8 hours post attachment.  
Overall, Alchornea cordifolia exhibited antiviral activity against HSV2, having the 
highest potential for plaque reduction in the 30% Methanol fraction, yet the inhibited events 
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 According to the World Health Organization (47) about 13% of people aged 15-49 
worldwide are infected with HSV2 and it cannot be cured, only treated with antiviral drugs. The 
WHO goes on to explain HSV2 is primarily sexually transmitted and can be asymptomatic or 
cause painful blister/ulcers at the infection site. The shedding of HSV2 is episodic and varies by 
individual, and sometimes infection can go unrecognized (38). This can result in spreading of the 
virus unknowingly by asymptomatic carriers, or individuals who present the infection with mild 
to no symptoms. The National Center for Health Statistics reports that more women are suffering 
from this infection than men, which is cause for concern when considering the possibility of 
spread during birth resulting in neonatal herpes (25). Another potential complication of HSV2 
infection is the increased risk of acquiring HIV-1 when coupled with the viral shedding of HSV2 
(47). It is found that HSV2 infection directly increases the susceptibility of an individual to HIV-
1 by affecting the function of Langerhan cells even when an individual is not exhibiting 
symptoms (24). HSV2 remains latent and has no cure. It is a lifelong infection that individuals 
have to deal with and address for the rest of their lives. This leads to another aspect of HSV2 
infection, which is psychosocial impact. The stigma surrounding HSV2 can result in many 
complications outside of the symptoms presented due to infection such as painful blisters and 
ulcers (47). The recurrent nature of the virus lends to the increased stigma placed on those who 
are infected having the possibility of causing distress, lower self-esteem, and depression (28). It 
is also noted many individuals feel anxiety surrounding disclosure to future partners which aids 
to the continued spread of the virus due to failure to disclose the risk of infection to individuals 
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not yet exposed (6).  Due to the widespread nature of HSV2, the lifelong infection resulting from 
latency and flares, the stigma attached and resulting behavior, and the complications that can 
rise, HSV2 infection is cause for notable concern and necessity of treatment options as well as 
possible preventatives.  
 Plants have been used to treat various diseases and ailments since civilization arose, and 
continues to be utilized (17). Alchornea cordifolia, commonly known as Pennah, is a plant 
widely found in Africa and used in traditional medicine (8). Some common uses in medicine 
include antibacterial, antidiarrheal, anti-inflammatory, and pain management, as well as against 
malaria and fevers (8). Common ailments treated are venereal diseases such as gonorrhea, 
urinary tract infections, cough, sore throat, ulcers and inflammation (8). Though research has 
been done into antibacterial, antiplasmodial, and antifungal uses for this plant, antiviral research 
has yet to be accomplished. The very little work completed in antiviral studies with Pennah was 
with HIV-1 and HIV-2 infections and showed that the plant inhibited HIV-1 and HIV-2 
replication, but more work would need to be done to further evaluate and utilize the plant against 
this virus (5).  
 Currently there are antiviral medications available to treat symptoms of HSV2 and reduce 
the frequency and severity of the symptoms when they present including acyclovir, famciclovir, 
and valacyclovir (47). There is a push for vaccine development to aid in prevention of initial 
infection of HSV2, as well as research into a topical microbicide that would prevent infection 
when topically applied before possible exposure (32). Research into the possibility of antiviral 
activity present in Alchornea cordifolia (Pennah) against HSV2 could uncover the potential for 






A majority of the human population (close to 100%) are infected or have been infected 
with a herpesvirus, a testimony to the widespread impact of this family of viruses (18). 
Herpesviruses got their name from the Greek herpein meaning “to creep” due to their ability to 
lay latent in the infected individual (34). This characteristic is what they are known for: 
establishing latency in an individual after initial infection, resulting in a lifelong recurrent viral 
shedding and possible recurrence of symptoms (23, 34). HSV2 is one of the three neurotropic 
herpesviruses that infect humans, others being herpes simplex virus type 1 (HSV1) and varicella 
zoster virus (VZV) (40). Resulting symptoms can include painful blistering and open sores, 
while some individuals do not show symptoms, but still undergo viral shedding as reported by 
the World Health Organization (47). The virus can be brought out of latency due to stimuli or 
sporadically (33). The latency of these viruses can result in severe, sometimes fatal, conditions 
for an individual in the future including shingles (from VZV), encephalitis and corneal blindness 
(from HSV1), and meningitis (from HSV2) (7, 40). Immunocompromised individuals (such as 
HIV sufferers) are more susceptible to recurrence and serious symptoms due to decreased 
immune response and ability (7, 47). The prevalence and ease of spread, especially due to 
asymptomatic carriers with established latency, and possibility of reemergence and cause of 





Properties of herpesviruses 
 Herpesviruses are nuclear replicating and are characterized as large enveloped double 
stranded DNA (dsDNA) viruses that can establish latency proving to be lifelong infections (7, 
23, 40, 44, 47). Over one hundred different species of Herpesviridae have been uncovered, and 
of them there are eight herpes viruses that have been identified to infect humans, three of which 
are neurotropic (2, 23, 40). Across all viruses included in the Herpesviridae family there is a 
similar replication cycle, common structure, and the ability to establish latency, which includes 
periodic reactivation and viral shedding (23). Though all herpesviruses are common in those 
ways, they vary in others including cells they infect and remain latent and gene content resulting 
in three subfamilies: alpha, beta, and gamma (35). Herpesviruses are large being about 100-200 
nm in size, icosahedral capsid shape, and considered complex regarding human viruses (18, 34). 
The dsDNA contains about 125-260 kbp which then encode roughly 70-200 proteins (18, 34). 
The basic structure includes a core containing the dsDNA inside an icosahedral protein capsid 
wrapped in another protein layer called the tegument encased by a final lipid envelope (16, 34). 
Throughout the many herpesviruses there are different sites of primary infection resulting in a 
range of symptoms depending on the specific virus within the family (7). Herpesviruses are host 
specific and have adapted to infect the host and continue to remain until end of life (34).   
 Herpes simplex virus type 2 belongs to the subfamily Alphaherpesviridae (35). They are 
known to have a short replication cycle that is completed in hours and establish latency in the 
sensory nerve ganglia in the host, specifically the dorsal root ganglia for HSV2 infections (40, 
45). While neurons are important cells for establishing latency, epithelial cells also play a key 
role concerning infection and spread through mucosa (18). There are four main components 
making up the structure of a HSV2 virion: the core contains linear dsDNA, the icosahedral 
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protein capsid, the tegument, and the lipid envelope containing viral glycoproteins (34, 35, 38, 
39, 45).  
 
Herpes simplex type 2 Replication Cycle 
 The replication cycle of HSV2 is considered short in respect to other herpesviruses and is 
characterized as lytic and latent (7, 46). As an overview HSV2 goes through a typical viral 
replication cycle that includes binding/attachment to a susceptible host cell, penetration, 
uncoating, replication, assembly, and release of mature virion (12, 14). 
1. Attachment 
Viral attachment occurs when HSV2 comes in contact with a susceptible tissue having the 
receptors necessary for the glycoproteins on the envelope of the virion to bind (45). There are 
twelve glycoproteins (g) on the viral surface: gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL, gM, and 
gN (45). The glycoproteins known to be involved in the attachment process are gB and gC, 
which allow the virion to bind to the heparin-sulfated proteoglycans (HSPGs) located on the cell 
surface (2, 43, 45). The initial bond with the cell surface receptors (HSPGs) is with gC, but in 
virions with a gC deficit gB can take over the roll resulting in decreased binding (1, 2, 43). 
Following the attachment to the HSPGs, gD binds to the other cellular receptors to strengthen the 
bond (43). The cellular receptors binding to gD that have been identified are: HveA/HVEM 
(herpes virus mediator) which is a part of the tumor necrosis factor receptor family (TNFR), 
Nectin1, and 3-O sulfated heparan sulfate, a modified heparin sulfated proteoglycan (2, 13, 43, 
45). After the initial attachment facilitated by gC and gB, gD will interact with its receptor and 
initiate a conformational change resulting in a complex of gB and gH/gL to function in the fusion 
of the cellular and viral membranes (1, 43, 45). 
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2.  Penetration 
The entry process, or penetration, for HSV2 following attachment takes the form of viral 
fusion since HSV2 has a lipid envelope that can fuse with the cellular lipid membrane (1). The 
fusion of the viral lipid envelope and the cellular membrane is triggered by the binding of gD 
with one of the co-receptors, HveA/HVEM, Nectin-1, or 3-O sulfated heparan sulfate that causes 
the formation of a complex including gB, gH and gL allowing for fusion of the membranes and 
viral entry (1, 2, 43). The formation of the complex due to the gD binding results in the fusion of 
the membranes and eventual release of the capsid and tegument into the cytoplasm of the cell 
(43, 45).  
3. Uncoating 
Viral uncoating can occur once the capsid is transported to the nucleus by associating with 
microtubules (43, 45). While much of the tegument is disassociated (exception including VP1/2) 
to allow for docking at the nuclear pore complex (NPC) where the dsDNA is inserted into the 
nucleus in the nucleoplasm (14, 43, 45). The release of the viral linear dsDNA into the nucleus is 
termed uncoating (14). 
4. Replication 
Once the viral capsid is inside the nucleus, accompanied by the tegument protein VP16, it 
will begin the process of viral replication (29, 43). The viral protein VP16 acts as a transcription 
activator, or transactivator, by promoting the transcription and regulation of the viral immediate-
early (IE) genes by recruiting transcriptional factors (9, 29, 45). There are three types of genes 
transcribed and translated by the host cellular machinery grouped by the order of viral protein 
expression (21, 36, 45). Once the viral proteins are transcribed, they exit the nucleus and enter 
the cytoplasm where they are translated, then reenter the nucleus to function in the viral 
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replication (36). The first wave of proteins transcribed are called the immediate early genes 
termed alpha, which can be transcribed due to host encoded factors and play a role in reducing 
host antiviral reactions and promoting the transcription of the next wave of viral proteins (21, 36, 
43). Included in the alpha viral proteins are Infected Cell Proteins (ICPs) 0, 4, 22, 27, and 47 (21, 
36). The next wave of viral proteins transcribed are the early genes, which are given the grouping 
beta (43). The beta genes promote the replication of the viral genome (43). The last wave of 
expression is termed the late genes, or gamma, which are mostly structural proteins that will 
comprise the mature viral particle therefore some do not reenter the nucleus but instead insert 
into the membrane of the rough endoplasmic reticulum and are glycosylated (21, 36, 43). Alpha 
genes reach their peak production at around 2-4 hours post infection, beta genes reach their peak 
production at 6-12 post infection, and gamma genes reach peak production at around 10-16 hours 
post infection (21). 
 Once the viral capsid enters the nucleus and the genome is released the linear dsDNA 
undergoes circularization necessary to produce progeny virions because the dsDNA does not 
elicit the double strand break response needed to replicate the DNA (31). This results in “rolling 
circle” replication of the circular concatemeric viral DNA that results in the linear copies of viral 
genome ready used in the packaging of new virions (21, 31, 43, 44, 45). 
5.  Assembly, Maturation, and Release 
Assembly of the viral particle starts within the nucleus with the assembling of the capsid 
(21). The capsid is first assembled without containing the viral DNA, which is then (with the 
help of viral proteins) packaged inside the empty assembled capsid (21, 45). This can result in 
some capsids not getting packaged with DNA making them non-infectious (21). It is cited that 
the capsid then becomes enveloped in the inner nuclear membrane and then become de-
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enveloped at the outer nuclear membrane as a way of exiting the nucleus as an assembled capsid 
into the cytoplasm (22, 27, 43, 45). The capsid acquires the tegument proteins in the nucleus and 
in the cytoplasm (22, 43). The capsid that had been enveloped in the inner nuclear membrane, 
then de-enveloped by the outer nuclear membrane, is now enveloped a second time in the trans-
Golgi network (TGN) membranes through budding (21, 22). The trans-Golgi network 
membranes contain glycoproteins that are derived from glycoproteins translated into the 
endoplasmic reticulum during replication (22, 43). The now enveloped mature virion is 
transported to the cell surface by the TGN vesicle that fuses with the cellular membrane, 
releasing the enveloped mature virion (26). 
 
Current Treatments 
The high prevalence of herpes simplex viruses, like HSV2, calls for varying treatment 
options. This widespread infection remains latent causing the re-emergence of symptoms in 
many individuals. Antiviral drugs have been made available for the treatment of these symptoms 
and in some uses to suppress the flares, but none have been found to cure the infection (47). 
Antiviral drugs available for treatment of HSV2 include acyclovir, penciclovir, valaciclovir, and 
famciclovir, all of which are considered effective and can be utilized to alleviate symptoms and 
suppress episodic reemergence of HSV2 (3, 10, 37, 47). Though these antiviral drugs have 
proven effective at shortening the duration of symptoms and suppressing recurrent episodes they 
do not cure the infection therefore do not extinguish chance of transmission, and some resistance 
to the antiviral drugs has been noted rendering the antiviral drugs less than totally effective (10, 
19). Each drug targeting HSV2 as an antiviral is showing action against DNA polymerase (41). 
There has been notable emergence of drug resistant HSV2 against acyclovir seen especially in 
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immunocompromised individuals taking this drug long term and regularly (41). There is 
continued support into further investigation of naturally occurring substances that prove effective 
as an antiviral, specifically against HSV (3). 
Ethnomedicine has been practiced throughout the ages showing success in utilizing 
natural substances against various infections and diseases (17). Plants have been used to treat 
bacterial, fungal, viral, and plasmodial ailments by trial and error for the people utilizing the 
ethnomedicinal strategies (8, 17, 30). Naturally occurring substances proving to have antiviral 
properties have been identified through the exploration of ethnomedicinally used plants (30). 
Some examples of plants demonstrating antiviral activity are: Geranium sanguineum L. (against 
influenza virus), Trichilia glabra L. (against vesicular stomatitis virus), and Boehmeria nivea L. 
(against hepatitis B) (20, 30). There has also been research into the possibility of antiviral 
activity in Carissa edulis against HSV1 and HSV2 (30).  
Alchornea cordifolia (Pennah) has long standing been a useful plant in regard to 
ethnomedicine showing great use as an antibacterial, antiplasmodial, and antifungal (8). Though 
there has been limited research done into its antiviral capabilities, Alchornea cordifolia has also 
shown promise as a potential antiviral in studies such as one done demonstrating antiviral 
activity against HIV-1 and HIV-2 in inhibiting viral replication (5). Another use of Pennah as an 
antiviral was investigated showing antiviral activity against respiratory syncytial virus (15). The 
spanning use of Pennah as an antimicrobial as well as some investigation into antiviral potential 
coupled with the need for more and naturally occurring treatment options against HSV2 appeals 





Materials and Methods 
 
Preparation of Plant Extract 
Crude Alchornea cordifolia (Pennah) is obtained from the Congo. The plant material that 
was previously dried and stored was loaded into a cellulose extraction thimble. Soxhlet 
extraction was done using chemicals in sequence of organic solvent (a mixture of Methylene 
Dichloride (DCM), and Hexanes 1:1), followed by methanol, then water. Soxhlet extraction is 
used with a methanol solvent (1000 mL) to obtain the methanol fraction (MeOH) from the crude 
Pennah extract, which is dried in a drying oven and then collected in a scintillation vial.   
 
Chromatographic Extraction on C-18 column 
 C18 column chromatography was used to further separate the Pennah MeOH extract 
using a methanol step gradient. First, Pennah MeOH extract (200 mg) was dissolved in 25 mL of 
dH2O. The extract that did not go into solution was then dissolved using 15 mL of 100% 
methanol. Once equilibrated, the C18 was then washed with 100% methanol, then dH2O. The 
extract dissolved in methanol was then washed through the C18 three times and collected. Then 
30 mL of dH2O, 10% methanol, 20% methanol, 30% methanol, and 100% methanol were run 
through the column, in that respective order. After each was washed it was collected resulting in 
collections from each was labeled according to the solution used for the collection. Each elution 




Thin Layer Chromatography  
 Thin-layer chromatography (TLC) was employed using the extract to visualize how many 
components may be apparent in the sample. The extract was dissolved in either dH2O or MeOH, 
then centrifuged. The supernatant was collected and used for spotting on the silica plate in 5 µL 
increments. The chamber was equilibrated with a wick, then the dried spotted silica plate was 
placed in the chamber with the solvent and left until the solvent reached the designated cut off 
point near the top of the silica plate. After running in the solvent, the plate was dried on a hot 
plate. The plates were viewed under long wave length ultraviolet light (365 nm) and short 
wavelength ultraviolet light (254 nm) to visualize bands. 
Solvents used were: 
Ethyl acetate : dH2O : formic acid : glaciel acetic acid (85:8:4:3) 
Ethyl acetate : formic acid : glaciel acetic acid : dH2O (100:11:11:27) 
Dichloromethane : methanol (50:50) 
 
Testing for Chemical Class of Compound Present in Extract 
 Alkaloids were tested for in the Pennah MeOH extract is by preparing Dragendorff’s 
Reagant and using 25 µL combined with 0.5 mL of dH2O and 25 µL of Pennah MeOH extract. 
An orange precipitate indicates the presence of alkaloids. 
 Phenols are tested for by adding 25 µL of Pennah MeOH extract to 0.5 mL of Ferric 
chloride solution. Blue/green coloration indicates the presence of phenols.  
Flavonoids are tested for using the Shinoda test, and pink or red coloration indicates 
presence of flavonoids.  
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Terpenoids are tested for using the Leibermann-Burchart test, and a green or green blue 
coloration or precipitate indicates presence of terpenoids. 
 
Cell Culture 
The Vero cell line (African green monkey kidney) was propagated and maintained with 
Dulbecco’s Modified Eagle Media (DMEM) with added antibiotic/antimycotic, non-essential 
amino acids, sodium pyruvate, and 10% Fetal Bovine Serum (FBS). They were incubated in 
37C in 5% CO2 until confluent monolayers formed. Once the cells formed a confluent 
monolayer on the cell culture flask, the cells were washed with phosphate buffer saline solution 
containing EDTA. The cells were then incubated in trypsin until the cells released from the flask. 
The mixture of cells and trypsin collected, centrifuged, resuspended in DMEM, and 
redistributed. The number of cell passages is limited, observed when the cells display 
morphological and/or physiological abnormalities. 
 
Virus 
 Herpes Simplex Virus Type 2 (HSV2) was propagated in Vero cells. The stocks were 




 Viral assays were done using plaques to obtain results that quantified and determined the 
presence of antiviral activity. Vero cells were grown in 25 cm2 culture flasks (t-25) to confluent 
monolayers. Confluent monolayered flasks were important for viral plaque assays because 
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plaques form from the infection of one cell and the viral production then infecting subsequent 
surrounding cells due to close proximity and higher probability of the viral particle coming in 
contact with the closer cells first to infect. The virus stored in -70C is thawed and diluted to a 
working dilution of 100-150 pfu with DMEM without serum. The working dilution of virus is 
used to infect the confluent t25 flasks and incubated for 1 hour in 37C. A negative control flask 
is infected with the same volume of DMEM without serum as virus was used in the positive and 
treated flasks. After incubation the virus is decanted and the flasks are washed with DMEM 
without serum to wash away unattached virus. Positive and negative control flasks were fed with 
DMEM with 10% FBS. Treated flasks were fed with varying concentrations of Pennah extract 
(such as 1000µg/mL) dissolved in 20µL of DMSO and diluted with DMEM with 10% FBS. 
Flasks were incubated for 48-72 hours in 37C.  
This incubation time was used to allow for enough time and subsequent infections of 
surrounding cells to result in plaques that were visible by viewing with the eye after staining. 
The amount of time given allowed for enough viral cycles and subsequent infections in 
surrounding cells that gave a clear visible plaque, but not plaques that were too large and 
indistinguishable from each other. After 48-72 hours of incubation the flasks were observed 
individually for signs of cytopathic effects (CPE) and potential plaque formation. Plaques were 
counted and recorded for each flask. The plaques were able to be counted and recorded because a 
plaque was formed and considered to be an area on the monolayer that has the absence of cells. 
Therefore, after the crystal violet stains the remaining living Vero cells purple, the areas with no 
cells due to viral infection and cell death left behind a clear area on the flask. These areas lacking 
cells were formed in a circular pattern due to the infection of one cell and viral production 
(which results in cell death) causing the infection of surrounding cells due proximity resulting in 
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the subsequent viral infection. This repeated until the end of the incubation period resulting in 
circular areas lacking cells due to the death. These areas considered plaques were then counted 
and compared. The negative should have none due to no viral presence, the positive controls then 
were compared to the experimental groups determining antiviral activity in the extract, or lack 
thereof. A positive control had only virus infection without application of extract, while the 
experimental groups had extract applied. The amount of plaques formed on each was compared 
as a way to qualitatively say plaque reduction (less plaques in extract treated groups) was or was 
not occurring, and by counting and calculation was a way to say how effective the extract was as 
an antiviral agent.   
 
Staining Protocol 
 After the 48-72-hour incubation period and observable viral plaque formation in positive 
controls the cells the flasks were decanted into a waste jar containing disinfectant. The flasks of 
cells were then fixed using 2.5% formaldehyde solution for 10 minutes, then stained with crystal 
violet (0.1% in 35% methanol) for 10 minutes. The flasks were rinsed three times with water 
then dried in the incubator. The observable plaques were then counted in each flask. The positive 
and experimental groups were compared using the below calculation for plaque reduction (R%): 
R% = [(Ppc-Pe)/Ppc] x 100 
R%: percent plaque reduction 
Ppc: plaque count in positive control 





 The post-adsorption, or post-attachment, assay was performed to determine if the extract 
showed antiviral activity against the virus by comparing the number of plaques in the positive 
controls to how many plaques developed in the treatment groups. Vero cells were grown in 25 
cm2 culture flasks (t-25) to confluent monolayers. The virus stored in -70C is thawed and 
diluted to a working dilution of 100-150 pfu with DMEM without serum. The working dilution 
of virus is used to infect the confluent t25 flasks and incubated for 1 hour in 37C. A negative 
control flask is infected with the same volume of DMEM without serum as virus was used in the 
positive and treated flasks. After incubation the virus is decanted and the flasks are washed with 
DMEM without serum to wash away unattached virus. Positive and negative control flasks were 
fed with DMEM with 10% FBS. Treated flasks were fed with varying concentrations of Pennah 
extract (such as 1000µg/mL) dissolved in 20µL of DMSO and diluted with DMEM with 10% 
FBS. Flasks were incubated for 48-72 hours in 37C. After 48-72 hours of incubation the flasks 
were observed individually for signs of cytopathic effects (CPE) and potential plaque formation. 
Plaques were counted and recorded for each flask. The viral assay is stained using 2.5% 
formaldehyde solution to fix the cells, and 0.1% in 35% methanol crystal violet. 
 
Post-Adsorption Assay with Modifications to Time Cells were Exposed to Extract 
 These assays are carried out as outline in the above section, with the exception of when 
the extract treatment is applied and removed from the cells after the 1 hour of incubation for viral 
attachment and wash. At certain time intervals the extract was added and removed from different 
treatment flasks. This gave information regarding how the extract may have affected viral 
replication. 
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A version which this assay was performed included specific time intervals surrounding 
the addition of plant extract on infected cells. Following 1 hour of incubation of confluent t25 
flasks of cells infected with 100-150 pfu of virus the flasks were washed. Each flask was fed 
with DMEM with 10% FBS until a specified time interval. At this point the flasks were fed with 
plant extract in DMEM with 10% FBS and incubated for 48 hours in 37C. At the end of the 
incubation time flasks were observed for CPE and plaque formation, fixed, stained, and plaques 
counted. 
 Another version of this assay was performed with the removal time interval of the plant 
extract modified. Confluent cells were infected with 100-150 pfu for 1 hour in 37C then washed 
with DMEM without serum. The flasks were then fed with extract diluted with DMEM with 10% 
FBS. At the end of the indicated time interval the flasks were washed with DMEM without 
serum and fed with DMEM with 10% FBS until the end of the 48 hour incubation in 37C. At 
the end of the incubation time flasks were observed for CPE and plaque formation, fixed, 
stained, and plaques counted. 
 
Neutralization Assay 
 In the neutralization assay the virus was combined with the plant extract before infection 
of the cells to determine if the plant extract neutralizes the virus. The plant extract was dissolved 
in 20 µL of DMSO and brought to desired concentration using DMEM with 10% FBS. Virus 
diluted to 100-150 pfu with DMEM without serum was combined with the plant extract and 
incubated for 20 minutes at 37C. Following the 20 minutes of incubation the mixture of plant 
extract and virus were used to infect confluent monolayer t25 flasks of cells. Positive controls 
were infected with a mixture of virus and DMEM without serum that incubated for 20 minutes, 
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and negative controls were infected with DMEM without serum that incubated for 20 minutes. 
After infection, the flasks were incubated for 1 hour at 37C then washed with DMEM without 
serum, and subsequently fed with DMEM with 10% FBS and incubated for 48-72 hours in 37C. 
At the end of the incubation time flasks were observed for CPE and plaque formation, fixed, 
stained, and plaques counted. 
 
Pre-infection Treatment Assay  
In the pre-infection treatment assay the plant extract was applied to the Vero cells 
overnight before infection of the cells to determine if pre-exposure to the plant extract had any 
effect on the cells that may affect the resistance to HSV2 infection. The plant extract was 
dissolved in 20 µL of DMSO and brought to desired concentration using DMEM with 10% FBS. 
The plant extract was applied to the confluent t25 flasks of the experimental groups, and DMEM 
with 10% FBS was applied to the positive and negative control confluent t25 flasks. After 
incubating at 37C overnight all t25s were decanted, washed with DMEM without serum, and 
infected with virus diluted to 150-200 pfu with DMEM without serum, with the exception of the 
negative control that was infected with DMEM without serum. After infection, the flasks were 
incubated for 1 hour at 37C then washed with DMEM without serum, and subsequently fed 
with DMEM with 10% FBS and incubated for 48-72 hours in 37C. At the end of the incubation 
time flasks were observed for CPE and plaque formation, fixed, stained, and plaques counted. 
 
Indirect Immunofluorescence Assays 
 Indirect immunofluorescence assays were performed to visualize the virus in the cells. 
The method utilized two sets of antibodies, a primary and a secondary. The primary antibody 
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attached to the viral antigen, with a secondary antibody following and attaching to the primary 
antibody. Following treatment with the primary and secondary antibodies the complex created 
can be observed under the fluorescence microscope. This method for visualization was used for 
observing viral production in extract treated cells compared to positive controls.   
 Cells at semi-confluency (around 50-60%) were used for indirect immunofluorescence 
assays to aid in visualization. Cells were washed twice with DMEM without serum that was kept 
on ice prior and for the duration use in this setting. When using this method to visualize viral 
replication at certain time intervals in extract treated versus positive control (no plant extract) 
treated cells the cells were infected with 100-150 pfu of virus and incubated for 1 hour in 37C. 
Following the incubation, the cells were washed with the DMEM without serum and fed with 
DMEM with 10% FBS. This counted as zero hours and at determined time intervals following 
the cells were fixed and treated with primary and secondary antibody. When using this method to 
observe attachment of the virus in extract treated cells compared to positive controls more virus 
was required so about 100,000-150,000 pfu was used. This high level pfu of virus was pre-
exposed to plant extract on ice for 20 minutes before infection of the cells. The cells were kept 
on ice and infected with the ice-cold mixture of extract and virus for 2 hours. After the 2 hours of 
incubation of the virus and extract mixture (virus and DMEM without serum for the positive 
control) on ice, the cells were washed three times with ice cold DMEM without serum. 
Immediately following being washed with SFM three times the cells were fixed and treated with 
primary and secondary antibody. 
 After cells were washed three times with cold DMEM without serum in either situation 
above, the cells were fixed with 5 mL of 2% formaldehyde. All cells in the experiment set were 
treated together. The formaldehyde is then decanted and 2-3 mL of DMEM without serum is 
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added to the flasks of cells and placed on the shaker for 5 minutes. Following the 5 minutes the 
cells are washed again twice more with 2-3 mL of DMEM without serum. This is the washing 
process used moving forward in this method. In cases of the first use of the method to determine 
viral production at certain time intervals the cells were then permeabilized with 5 mL of 100% 
methanol. This was decanted and the cells were washed using the shaker and subsequent 2 wash 
protocol. In the case of visualizing viral attachment kept under full cold conditions the 
permeabilization step is not used to help focus on just the attachment step of the viral cycle. 
Next, 3-4 mL of primary antibody (rabbit anti-HSV2) was applied to the cells and placed on the 
shaker for even distribution for 1 hour. Following, the cells were washed three times as described 
prior. About 3-4 mL of secondary antibody (goat anti-rabbit conjugated with 546 nm 
AlexaFluor) is then applied to the cells and left on for 1 hour on the shaker. Subsequently 
washed using the three-wash method and kept in 3 mL of DMEM without serum and refrigerated 
until viewed under the fluorescence microscope (Olympus IX71 inverted immunofluorescent 






















 Research on the antiviral activity of African traditional medicinal plants was conducted 
on crude and column fractionated extracts of Alchornea cordifolia (Pennah) against Herpes 
Simplex Virus Type 2 (HSV2) in Vero cells. The methanol extract was further fractionated using 
a C-18 silica in a flash column chromatography in an attempt to isolate the active compound. 
First, we had to establish what the major plant compounds that could be detected in the extracts.   
 
 Chemical Class of Compound Present in Extract 
Chemical analyses of the plant extract were performed to determine the possible presence 
of alkaloids, flavonoids, terpenoids, and phenols as described in the Materials and Methods 
section (Chapter 3).  
Crude Pennah MeOH Extract and30% Pennah MeOH Fraction  
Tested positive for the presence of alkaloids, phenols, and terpenoids and negative for the 
presence of flavonoids.  
  
Thin-Layer Chromatography  
 Thin-layer chromatography was utilized as a way to visualize potential number of major 
components in the plant extract, and in fractions that exhibited antiviral activity fractions. 




















Fig. 1: Displayed in A, B and C are images of TLC plates under the long wavelength UV light 
(365 nm). The TLC plates were run with the solvent ethyl acetate : dH2O : formic acid : glaciel 
acetic acid (85:8:4:3). Image A shows the crude Pennah MeOH extract (Lane 1A) with four 
distinct bands and the Rf values. Image B shows a comparison of the crude Pennah MeOH (Lane 
1B) run alongside 20% Pennah MeOH (Lane 2B) and 30% Pennah MeOH (Lane 3B). Lane 1B 
and 3B are being compared with a band at Rf value 0.925 appearing in both lanes. Image C 
depicts four lanes of increasing concentrations of 30% Pennah MeOH after being run twice in 
the solvent to further resolve the possibility of more bands. Lane 2C and Lane 3C show the 
bands the most resolved and bright enough to distinguish. 3B compared to 2C shows two bands 
at Rf values 0.963 and 0.913 resolved from the singular band at Rf value 0.925 following the 





























Detection for Antiviral Activity 
1. Post-Adsorption Assay 
 Post-adsorption, or post-attachment, assays were performed to determine if the plant 
exhibited antiviral activity after the Vero cells were exposed to HSV2 and time for attachment of 
the virus was allowed (1 hour) before treatment with plant extract was applied to the cells. 
Preliminary results of Crude Pennah (water extract and MeOH extract) in Table 1.  
 1a. Crude Pennah MeOH Extract 
Crude Pennah MeOH extract was applied to the cells after the initial infection to determine if the 
plant extract treatment would result in antiviral activity against HSV2. Results of this assay are 
displayed in Table 2.  
1b. Antiviral Activity in Crude Extract run on C-18 Colum eluted with MeOH   
Results of the experiments done to determine the plaque reduction potential of extract 
fractionated on C-18 column with increasing concentration of MeOH are shown in Table 3 and 
in Figure 2. 
 1c. 30% MeOH Pennah MeOH Extract 
Experiments were done to determine the plaque reduction potential of 30% Pennah MeOH using 
the post-adsorption assay. Results of the plaque reduction percentages when using the 30% 







Table 1: Antiviral Activity Screening in Crude Pennah 
µg/mL Crude Pennah Water  
Plaque Reduction (%) 
Crude Pennah MeOH  
Plaque Reduction (%) 
1000 95 100 
500 81 100 
250 65 100 
125 49 70 
Table 1: Antiviral activity as plaque reduction percentages after a post-adsorption screening of 
crude Pennah water extract and crude Pennah methanol extract against HSV2. Data shows 
antiviral activity in both crude extracts. Higher plaque reduction and more effective antiviral 
activity is observed in crude Pennah MeOH extract in comparison to the water extract. 
 
Table 2: Antiviral Activity in Crude Pennah MeOH 
µg/mL % Plaque Reduction 





Table 2: Resulting plaque reduction percentages displaying antiviral activity seen in crude 
Pennah MeOH against HSV2. At a concentration of 1000 µg/mL showed mild toxicity to the 
Vero cells, and at 500 µg/mL very slight toxicity to the cells. Concentrations under 500 µg/mL 
did not show toxic effects on the cells. 
 
Table 3: Antiviral Activity in the Collected C18 Fractions 
Fraction dH2O 10% MeOH 20% MeOH 30% MeOH 100% MeOH 
% Plaque Reduction  84 85.8 100 100 29.6 
Table 3: Results of post-adsorption screening with collected C18 fractions against HSV2 for 
determination of fraction with most antiviral activity potential to move forward with 
experimentally. Results of a screening done with 62.5 µg/mL at low pfu. Similar results 
indicated for 20% MeOH and 30% MeOH fractions necessitates further experimental evaluation 
at lower concentrations. 
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Fig. 2: This line graph displays the data collected during a post-adsorption screening against 
HSV2 in Vero cells of 20% Pennah MeOH fraction and 30% Pennah MeOH fraction to 
determine which fraction would be used moving forward. 
 
 Table 4: Antiviral Activity of 30% Pennah MeOH Extract  
 µg/mL % Plaque Reduction 








Table 4: Results of post-adsorption assay in the form of plaque reduction percentages of 30% 
Pennah MeOH against HSV2 in Vero cells. Demonstrates the antiviral activity potential of this 








































2. Neutralization of the infectivity of the HSV2 by 30% Pennah MeOH Fraction 
 Neutralization assays were performed to determine if viral exposure to the plant extract 
before infection would result in the neutralization of the infectivity of the HSV2 before 
application to the Vero cells. This type of assay was performed by combining HSV2 with plant 
extract and incubation for 20 minutes before using the mixture to infect the Vero cells. 
Results showed that 125 µg/mL of 30% Pennah MeOH extract neutralized 61.7% of HSV2. This 
data is referenced in Figure 5. 
3. Pre-infection Treatment Assay 
 A pre-infection treatment assay was performed using 30% Pennah MeOH to determine if 
the extract, when applied to the cells overnight before infection, would prove to be affective 
against HSV2 in the form of plaque reduction compared to positive controls. This assay was 
performed using concentrations of 125 µg/mL of 30% Pennah MeOH, and 250 µg/mL of 30% 
Pennah MeOH. Plaque reduction for 125 µg/mL was 28.8%. Plaque reduction for 250 µg/mL 
was 84%. Comparison of results of pre-infection treatment of cells with 30% Pennah MeOH and 
post-infection treatment of 30% Pennah MeOH can be found in Figure 3. 
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Fig. 3: The bar graph shows the comparison of percent plaque reduction seen pre-infection and 
post-infection against HSV2 in Vero cells of 30% Pennah MeOH plant extract. Pre-infection, 
which showed less antiviral activity, was when the cells were treated with 30% Pennah MeOH 
before infection with HSV2. Post-infection was when the Vero cells were infected with HSV2 
and then treated with 30% Pennah MeOH following the infection which showed more antiviral 
activity. 
 
4. Post-Adsorption Assay with Modifications to Time Cells were Exposed to Extract 
Time sensitive assays were performed with changes occurring the addition of extract and 
the removal of extract after initial infection (1-hour post incubation of virus and Vero cells). The 
extract used in these experiments was the 30% MeOH fraction Pennah MeOH (referred to as 
30% Pennah MeOH).  
4a. Addition of Extract at Different Time Intervals Post-Infection 
Vero cells were infected with HSV2 and incubated for 1 hour before being fed with DMEM with 
10% FBS.  Two hours after the infection some of t25 flasks were decanted and washed with 
SFM then 30% Pennah MeOH at a concentration of 125 µg/mL was applied and the flasks were 































30% Pennah MeOH Affects Pre- and Post- Infection
Pre-infection Post-infection
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group of the t25 flasks were decanted and washed with SFM then 30% Pennah MeOH at a 
concentration of 125 µg/mL was applied and the flasks were incubated until the end of the 48 
hour incubation time. The two groups of flasks with addition of plant extract at 2 or 8 hours was 
compared to the positive controls that were not treated with plant extract. The flasks with 125 
µg/mL 30% Pennah MeOH applied at 2 hours until end of incubation resulted in a plaque 
reduction of 54.5%. The flasks with 125 µg/mL 30% Pennah MeOH applied at 8 hours until the 
end of incubation resulted in a plaque reduction of 57%. These values are displayed in Figure 4 
and referenced in Figure 5. 
4b. Removal of Extract at Different Time Intervals Post-Infection 
Vero cells were infected with HSV2 and incubated for 1 hour before being treated with 125 
µg/mL 30% Pennah MeOH. Two hours after the application of the plant extract some of the t25 
flasks with the extract applied were decanted and washed with SFM, fed with DMEM with 10% 
FBS, and incubated until the end of the 48 hour incubation. The remaining t25 flasks that were 
treated with plant extract were incubated until 8 hours after application of extract at which point 
the plant extract was decanted, the flasks were washed with SFM, and then fed with DMEM with 
10% FBS and incubated until the end of the 48 hour incubation. The flasks that had the 125 
µg/mL 30% Pennah MeOH removed after 2 hours of treatment after initial infection resulted in a 
plaque reduction of 8.2%. The flasks with 125 µg/mL 30% Pennah MeOH removed at 8 hours 
after application of extract resulted in a plaque reduction of 11.5%. These values are displayed in 




Fig. 4: Percent reduction seen when treatment of 125 µg/mL of 30% Pennah MeOH wash was 
applied/removed at 2 hours, and 8 hours. This graph shows the difference in plaque reduction of 
the plant extract when utilized against HSV2 in Vero cells. 
 
 
Fig. 5: The bar graph represents the plaque reduction seen when utilizing 125 µg/mL 30% 
Pennah MeOH extract in varying types of plaque assays. Post-adsorption represents Vero cells 
treated with plant extract following infection of HSV2. The bar labeled neutralization is the 
resulting plaque reduction of cells infected with HSV2 combined with plant extract prior to 
infection with the combination. The addition bar represents the average plaque reduction 
observed after the addition of the plant extract at 2 and 8 hours. The removal bar represents the 





























125 µg/mL 30% Pennah MeOH Wash Applied/Removed at 



















Comparison of Plaque Reduction in Different Assay Types
125 µg/mL 30% Pennah MeOH
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5. Immunofluorescence Assays 
 Indirect immunofluorescence was the technique used to visualize HSV2 and its course of 
infection in Vero cells, and how that course would be affected by treatment of the plant extract. 
Positive control images were taken for reference in Vero cells that were infected with HSV2 and 
not treated with plant extract to visualize the progression of infection without treatment at certain 
time intervals of the viral infection. 
 5a. Immunofluorescence with Post-Adsorption Assay  
Results in Figure 6 demonstrate the comparison of HSV2 infection in Vero cells and HSV2 
infection of Vero cells that were treated with plant extract. Images in Column 2 (Images 2a-2c) 
show the resulting viral infection after 48 hours of incubation and after treatment with 125 
µg/mL of 30% Pennah MeOH. Column 1 (images 1a-1c) show the pattern of infection following 
the 48 hour incubation of HSV2 infected Vero cells with no treatment, considered positive 
controls. The resulting images show differences in the viral infection between the two groups. 
Both groups show cells infected with HSV2 because any visualization is due to the presence of 
the HSV2 virions. The cells in the positive control groups are shown to be in the later stages of 
infection and showing cytopathic effects of the cells balling up instead of being stretched out like 
the cells remained in the treatment groups as well as evidence of cell fusion resulting in 
multinucleated cells. Although the cells are infected in the treatment groups the virus at 48 hours 
post infection is not having the same balling effect on the cells. Another notable difference is 
where the abundance of virus is located in the infected cells at this point of infection. In images 
2b and 2c the area of the cells that has brighter fluorescence indicating more virus is the nucleus, 
while in images 1a-1c of the positive controls it shows the cells observed in those groups were 
characterized by larger amount of virus in the cytoplasm. Although some cells in the treatment 
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group had more virus in the cytoplasm (1c) the virus was more centralized in small clusters 
instead of dispersive throughout the cytoplasm like in the positive controls and those cells did 
not show the fusion of cells resulting in multinucleated cells like it did in the positive controls 
with virus in the cytoplasm.  
5b. Immunofluorescence with Post-Adsorption Assay with Time Modifications 
Visualizing the results for this assay are found in Figure 7. All groups were fixed at 28 hours 
post infection with HSV2. Images 5a and 5b are positive control images that had no treatment 
with plant extract at any point in the infection and are used for baseline and comparison images. 
The positive control images 5a and 5b show a field of view with many infected cells, as well as 
balling of cells occurring and fusion of cells resulting in multinucleated cells. Those are all 
indicative of normal CPE caused by HSV2 in Vero cells. It can also be noted the higher presence 
of virus in the cytoplasm of the cells diffuse when the cells are still stretched, and pushed to the 
outside when the cells are shown balled up with less amount of cytoplasm visible due to 
decreased surface area because of the balling effect caused by HSV2.  Rows 1-4 show cells 
treated with 30% Pennah MeOH (rows 1-2 with 125 µg/mL, rows 3-4 with 250 µg/mL) that 
were either added or removed at 2 or 8 hours. This was to reflect the resulting plaque reduction 
percentages seen as a result of the post-adsorption assay with time modifications. The cells 
treated with plant extract at 2 or 8 hours (1a-4a) have similar results and show less cells in the 
field of view infected with HSV2, as well as more virus in or around the nucleus than compared 
to the positive controls. This is reflective of the prior comparisons of the post-adsorption assay 
and is more characteristic of early stages of infection compared to the positive controls. In all 4 
images 1a-4a there are less cells in the field of view infected with HSV2, and between 1a-2a and 
3a-4a there are visibly less cells infected with HSV2 in the field of view in 3a-4a because it is 
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treated with a higher concentration of plant extract. This is demonstrating that the amount of 
plant extract used in experiments does have an impact on the antiviral activity and effectiveness 
of the plant on the viral replication of HSV2 in the Vero cells. This shows the extract at both 125 
µg/mL and 250 µg/mL and both added at 2 or 8 hours is affecting the viral replication in the 
Vero cells.  Images 1b-4b show cells with either 125 µg/mL or 250 µg/mL of 30% Pennah 
MeOH removed at 2 or 8 hours. Based on the plaque reduction percentage results of these groups 
from the assay performed it showed very little plaque reduction compared to the groups with 
extract added at these times. The plaque reduction percentage was between 8-12% when the 
plant extract was removed. These images are very similar to the positive controls in the number 
of cells infected in the field of view as well as some balling of cells and fusion of cells showing 
large multinucleated cells with viral presence mostly seen in the cytoplasm diffusely. Though all 
4 images are similar to the positive controls it is noted that the least number of cells infected in a 
field of view is in image 4b: the highest concentration of extract in the experiment and left on the 
longest before removal at 8 hours compared to 2 hours. This is demonstrated by these images 
showing very similar infection pattern and number of cells in the field of view infected when 
compared to the positive control images 5a and 5b.  
 
5c. Immunofluorescence with Neutralization Assay 
HSV2 at a high pfu of 100,000-150,000 was combined under ice cold conditions with the plant 
extract. 1000 µg/mL of 30% Pennah MeOH was used in equal quantities of virus combined on 
ice for 20 minutes before infection of flasks of Vero cells kept on ice for a total infection time of 
2 hours. Positive controls were infected with equal parts ice cold SFM and high pfu HSV2 and 
infected with the combination under the same conditions for 2 hours. At this time the cells were 
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fixed and treated for indirect immunofluorescence with the absence of the permeabilization step 
with 100% MeOH to ensure focus on the attachment of virus to the cells. Figure 8 shows the 
resulting images to further understand if the plant extract was preventing attachment of the 
HSV2 to the cells, resulting in less infected cells and therefore plaque reduction, or if the HSV2 
was still attaching and the plant extract was affecting another part of the viral replication cycle. 
Column 1 shows positive controls and Column 2 shows cells infected with virus combined with 
30% Pennah MeOH. 1a and 1b showing the positive controls displays pinpoint areas of 
fluorescence indicating high viral areas on the cells. Images 2a and 2b demonstrating the 
treatment groups show similar amounts of pinpoint fluorescence areas demonstrating the 
presence of viral attachment in the treatment groups comparable to the same seen in the positive 
controls. Based on the images it is shown that the attachment of HSV2 still occurs in extract 
exposed virus, meaning the plant extract is not interfering with the viral attachment step of the 












































Fig. 6: The images above are micrographs of indirect immunofluorescence utilized on a post-
adsorption assay. The images show Vero cells fixed at 48 hours post HSV2 infection. Column 1 
(images 1a, 1b, and 1c) displays pictures of positive control cells, which were infected with 
HSV2 and not treated with plant extract. The positive control images show cells that are in later 
stages of infection and showing signs of cytopathic effects (CPE) CPE visible in these images 
are balling of cells, more viral presence diffuse in the cytoplasm instead of the nucleus of the 
cells, and fusion of cells resulting in multinucleated cells. Column 2 (images 2a, 2b, and 2c) 
contains images of cells infected with HSV2 and subsequently treated with 125 µg/mL of 30% 
Pennah MeOH. In these three images at the same time of infection as the positive controls the 
cells are seen to be in earlier or less progressed infection stages. Most cells do not have the virus 
concentrated in the cytoplasm like the positive controls, and if they do (2a) they are not fused or 
multinucleated as well as showing more pinpointed areas of virus instead of diffuse in the 
cytoplasm. In cells exhibiting fusion and multinucleation (2b and 2c) the virus is not diffuse in 
the cytoplasm, but instead concentrated in the nucleus indicative of an earlier stage of infection 











Fig. 7: Displayed are micrographs of indirect immunofluorescence utilized on a post-adsorption assay with modifications to time 
cells were exposed to extract. All images represent Vero cells fixed at 28 hours post HSV2 infection. Rows 1 and 2 represent cells 
treated with 125 µg/mL 30% Pennah MeOH. Rows 3 and 4 represent cells treated with 250 µg/mL 30% Pennah MeOH. Row 5 
represents positive control cells that were infected, but not treated with any plant extract. 1a and 3a display cells with extract 
added at 2 hours post initial infection and left on for the 28 hours. 2a and 4a display cells with extract added at 8 hours post initial 
infection and left on for the 28 hours. 1b and 3b display cells with extract removed 2 hours post initial infection and subsequently 
fed with DMEM with 10% FBS for the 28 hours. 2b and 4b display cells with extract removed 8 hours post initial infection and 
subsequently fed with DMEM with 10% FBS for the 28 hours. Observe in the positive controls typical CPE of Vero cells infected 
with HSV2, such as balling and fusion resulting in multinucleated cells and more diffuse viral presence in the cytoplasm. In 
images 1a-4a showing the addition of extract there are much less cells in the field of view infected as well as presence of virus in 
the nucleus and concentrated virus around the nucleus instead of diffuse in the cytoplasm. Also note in images 1a-2a treated with 
lower concentration of plant extract more cells are infected showing the higher concentration of plant results in more antiviral 
activity. Note in images 1b-4b the cells are very similar to the positive controls with many cells in the field of view infected and 






































Fig. 8: Micrographs depicting indirect immunofluorescence utilized on a 
neutralization assay with a high pfu of 100,000-150,000 and a 2-hour incubation time 
on ice before Vero cells were fixed. Column 1 represents the positive control cells 
with no plant extract and virus combination. Column 2 represents cells infected with 
the virus in combination with 1000 µg/mL 30% Pennah MeOH. In images 1a and 1b 
the positive controls pinpoints of fluorescence are indicative of viral attachment to the 
cells in the field of view. The time of exposure to HSV2 and under the ice-cold 
conditions it only allowed for attachment to occur without penetration to result in 
visualization of attachment of virus in cells and nothing further. The positive images 
showing the pinpoints compares to images 2a and 2b which show the infection of the 
Vero cells under the same conditions as the positive with the exception of plant 
treatment and combination with the virus. Infecting with the combination, like in the 
neutralization assay which showed antiviral activity, and comparing to the positive 
controls allows for confirmation or elimination of the possibility the plant extract is 
interfering with the attachment of the virus and causing the antiviral activity in that 
manner. Images 2a and 2b show the pinpoint areas of fluorescence at similar 
quantities in the field of view indicating the presence of attachment in the treatment 






 The African plant, Alchornea cordifolia (Pennah), has extensive ethnomedicinal uses 
including antibacterial, antifungal, and antiplasmodial. There have been limited studies into the 
antiviral capabilities of this plant extract, but the ones done have shown promise of antiviral 
activity in Pennah extract. In this experiment the water and methanol extracts of crude Pennah 
were screened for antiviral activity against herpes simplex virus type 2 (HSV2) in Vero cell 
lines. Both extracts were screened for antiviral properties by the use of plaque reduction assays. 
The plaque reduction assay used for screening was a post-adsorption assay. Post-adsorption 
assays allow for the binding of the HSV2 virions to the Vero cell before application of extract. 
This demonstrates whether or not the extract is viable as an antiviral following initial attachment 
of the virus. The idea behind this approach is that once the virus is allowed to infect cells prior to 
the application of any potential antiviral compound(s), any reduction in the number of plaques 
must be due to the interference of the applied compound(s) with any of the steps of virus 
replication inside infected cells (uncoating, replication, assembly, maturation, and release). The 
methanol extract exhibited higher plaque reduction results and more effective antiviral 
capabilities than the water extract, though the water extract also showed antiviral activity against 
HSV2. The Pennah MeOH extract was then further studied to gain a preliminary understanding 
of the effect it has as an antiviral on the viral replication cycle, and further investigation into the 
fraction that is most effective against HSV2 in an attempt to uncover the active principle. 
 Continued screening using post-adsorption assays was the method of distinguishing 
which fraction of the Pennah MeOH extract contained the most antiviral compounds effective 
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against HSV2. A non-polar C-18 column was used to separate Pennah MeOH extract into several 
subfractions by eluting with H2O followed by various water-methanol mixtures of increasing 
methanol strength (10% -100% in 10% increments).  Each fraction was collected and screened to 
determine which was the most effective as an antiviral; the 30% MeOH (30% Pennah MeOH) 
fraction displayed the most antiviral activity against HSV in our basic screening methods. The 
20% MeOH fraction also showed appreciable amount of reduction, but not as effective as the 
30% Pennah MeOH fraction. This could be of further interest to investigate the properties and 
components of both fractions in future research. Now that the fraction of the extract was 
narrowed down further from crude methanol extract, experiments to gain a better idea of how the 
extract was interfering with the viral replication cycle were undertaken, but not completed. 
A basic understanding of the viral replication cycle of HSV2 should be established before 
moving forward to recognize the possible ways Pennah is interfering and exhibiting antiviral 
activity. In order to produce infectious viral particles, the biochemical steps of HSV2 replication 
need to proceed without disruption. There are multiple steps at which the extract could be 
interrupting the replication of HSV2. The viral particles attach to the cell, this step requiring no 
exchange of energy and is not dependent on temperature. After attachment and binding of the 
viral particle to the host cell, in this case Vero cells, the virion must penetrate the cellular 
membrane and release the genome containing capsid into the cytoplasm. The viral particle is 
capable of attaching to the Vero cell without further penetration to occur resulting in a possible 
point of interference by the extract. Following penetration, the capsid is transported to the 
nucleus where uncoating occurs and the genetic information is inserted into the nucleus to allow 
for replication. Along the way multiple tegument proteins play a role in the process. Once the 
genome and proteins are replicated and translated the assembly occurs in the nucleus. After 
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release from the nucleus maturation occurs in the cytoplasm where the viral particle gets 
enveloped and exits the cell by exocytosis (14, 21, 43, 45). 
 Assessing the capabilities of Pennah as an antiviral and the ways in which it remained 
effective was done by varying types of plaque assays. The dependent factor in most of the assays 
was the factor of time. The point at which the virus and extract come in contact, and the whether 
or not the application of extract occurred post infection, or pre-infection, were considered when 
experimenting with the extract and HSV2 on Vero cells. Treating with the extract at different 
time intervals began illustrating the capabilities of the plant as an antiviral. When discussing the 
antiviral activity and plaque reduction of this fraction the concentration of 125 µg/mL of 30% 
Pennah MeOH will be the referenced results due to its higher degree of reproducibility 
throughout assays. From here forward all percentage of plaque reduction in reference to an 
experiment will be with treatment of the concentration 125 µg/mL of 30% Pennah MeOH, unless 
specified otherwise. 
 The pre-infection assay showed some antiviral activity at 28.8%, which is less than half 
of what shown when compared to a post-infection treatment assay (64.5%). Though there is 
some antiviral activity present in the resulting pre-treatment of cells overnight, it can be 
attributed to a few factors. The wash of the cells after incubation with the plant overnight may 
not have been fully effective at washing all of the present plant extract off the cells, possibly 
leaving some extract behind to interact with the virus. This would be reflected in the lessened 
plaque reduction in comparison to post attachment exposure and continued treatment for the 
duration of the assay. In addition, further experimentation showed comparable plaque reduction 
in neutralization assays and post-adsorption assays suggesting the extract is associating with the 
virus, not the cells themselves, as an antiviral. 
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 The neutralization assay showed 61.7% of free virus was neutralized by 30% Pennah 
MeOH when combined and incubated pre-infection. This data suggests that the direct application 
of the extract on virus particles inactivates/damages the free virions in some way interrupting 
future events in the viral replication cycle, especially the attachment step and to a lesser extent, 
the penetration. Attachment was considered the step interrupted at first, but through 
immunofluorescence assays this was disproved. Attachment is not temperature dependent, but 
penetration is. Through application of high concentration virus to cells under ice-cold conditions 
and maintained at this temperature to allow virus attachment which can be visualized with 
indirect immunofluorescence as attached virions could be seen as fluorescing specks, dots or 
clumps on infected cell surface. Micrographs of this assay depicted small pinpoint areas of 
fluorescence indicating viral attachment did occur. Since attachment was indicated through an 
indirect immunofluorescence of a neutralization assay this means that another step of the viral 
replication cycle is disrupted by the extract, ruling out attachment as the affected step.  
 Post-adsorption assay shows the effectiveness of the extract as an antiviral against HSV2 
in Vero cells after the virus has time to attach and in the presence of the extract for the duration 
of the incubation and assay. At concentrations higher than 500 µg/mL the extract shows slight 
toxicity to the cells, the most being at 1000 µg/mL. Though the methanol extract may show some 
slight toxicity at these concentrations it does prove to be extremely effective as an antiviral 
agent. Even at 250 µg/mL the plaque reduction is 97.8%, which is almost no plaque forming 
units. At concentrations as low as 7.8125 µg/mL the extract still exhibits antiviral abilities 
against HSV2 at a plaque reduction of 11.2%. The decrease in plaque reduction as a function of 
decrease in concentration shows that the components of the plant and how much is available 
reflects in the effectiveness of the treatment. This demonstrates that the extract is causing the 
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plaque reduction. This is also shown in the results of the immunofluorescence assay comparing 
micrographs of cells treated with 250 µg/mL and cells treated with 125 µg/mL at 28 hours post 
infection. The higher plaque reduction the post-adsorption assays showed was reflected in these 
images indicating less cells per field of view fluorescing as a way of showing less spread and 
infection in the cells treated with 250 µg/mL.  
 Further exploration into the part of the viral replication cycle affected was done by 
performing time sensitive post-adsorption assays. At 1 hour post-infection the viral particles 
have attached. At 2 hours post-infection the virion has penetrated the cells and are located within 
the cells. At 8 hours post-infection viral particles are assembling the proteins and genetic 
material that are being replicated and translated, and not likely that any have exited the cells. At 
10-12 hours the assembled virions start releasing, and by 24 hours the total yield is typically 
released. The new viral particles then infect surrounding cells and the cycle continues until total 
cell death, or for experimental purposes until the cells are fixed (48 hours when countable 
plaques have developed). Adding the 30% Pennah MeOH to the cells following 2 hours post-
infection and 8 hours post-infection proved almost as high plaque reduction as addition to the 
cells 1 hour post-infection (average 55.75%). Removing the treatment at 2 and 8 hours post-
infection shows substantial decrease in plaque reduction at a low average 9.85% reduction. That 
means when the extract was applied at either 2 or 8 hours there was over a 50% reduction in 
plaques compared to cells not treated with the extract at a concentration of 125 µg/mL. When the 
extract was applied 1 hour post-infection, then removed 2 hours or 8 hours later less than a 10% 
reduction in plaques was observed compared to positive controls with no extract (125 µg/mL) 
applied. These results were supported with micrographs taken of immunofluorescence assays 
depicting these experiments. Micrographs showed less infected (fluorescing) cells with the 2 and 
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8 hour addition groups than the positive controls. The 2 and 8 hour extract added micrographs 
were comparable to micrographs taken of cells with treatment added 1 hour post-infection and 
left on until cells were fixed. This reflects the very similar plaque reduction percentages seen 
with countable plaque assays (55.75% compared to 64.5%). The micrographs of removal of 
treatment at 2 and 8 hours closely resembled and showed no apparent differences to the positive 
control images, which was supported the limited plaque reduction seen in the assays performed 
(9.85% compared to 64.5%). This set of data is important in drawing conclusions to what part of 
the replication cycle is thought to be interfered with by the extract.  
 Through indirect immunofluorescence and neutralization assays it has been determined 
that attachment of the virus is not interrupted by the presence of the extract. Based on the time 
sensitive assays, and considering neutralization of free particles showing comparable plaque 
reduction, the viral particles need to be exposed to the plant extract to be effective before 
attachment or penetration. When considering the assays performed it is easy to think the extract 
is interrupting attachment, but this is proven false with indirect immunofluorescence. Something 
important to note is that initial infection and production of viral particles does not encompass the 
entire scope of the HSV2 infection and plaque forming process. Plaques are formed by infection 
of a Vero cell that results in virulent viral particles and cell death, that then infect the 
surrounding Vero cells and produce more infectious virions and cause more cell death, and so on 
until a visible plaque is formed on the flask. That means enough cells in an area have to go 
through subsequent infections from the initial starting cell infection to create a plaque visible to 
the eye. Therefore, initial infection may occur and produce subsequent viral particles that are 
then affected by the plant extract’s antiviral properties. Taking this possibility into consideration 
presents challenges when determining which part of the viral replication cycle is being disrupted.  
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Through the assays it is clear that the extract interacts with the virus, and when the plant 
extract was not applied before attachment, and was not available for interaction for the 
subsequent viral particles, little plaque reduction was observed (removing after 2 and 8 hours 
after attachment). Though the extract may not prevent attachment, it may interfere with some of 
the surface proteins necessary for penetration to occur. The viral particle binds due to 
interactions between the receptors on the cell’s surface and glycoproteins on the envelope of the 
virion. After this binding, more glycoproteins (gD, gH/L) are involved to allow for penetration. 
Once gC binds, gD must bind to one of its co-receptors (HveA/HVEM, Nectin-1, or 3-O sulfated 
heparan sulfate) to allow for the fusion of membranes and viral entry (l, 2, 43). The extract could 
interfere with this process and result in viral attachment, but no subsequent penetration, therefore 
halting the infection by that virion. The viral particle could also associate with the extract before 
attachment and still penetrate leading to disruption of other early replication events such as 
uncoating, replication, or assembly. Limited time and resources did not allow for further analysis 
in determining the specific viral replication cycle event being interfered with resulting in the 
antiviral activity.  
 Two techniques were used to analyze the composition of the extract. Chemical detection 
methods were used to determine what class of compounds may be present in the extract. The 
methods used determine the presence of large quantities of the chemical classes and do not 
necessarily detect the presence of every single type of compound within the class. More directed 
and advanced methods would be necessary to grasp every compound present in each class. The 
30% Pennah MeOH extract tested positive for alkaloids, phenols, and terpenoids with the 
methods used. Testing for flavonoids gave a negative result in this experimentation. Alkaloids, 
terpenoids, and phenols have all been found to contain compounds that have acted as antivirals 
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making their presence in the extract of interest possibly contributing to the antiviral activity or 
containing the compound that may be causing the antiviral activity (4, 11, 42). 
Preliminary thin-layer chromatography was attempted to distinguish how many major 
components of the plant extract were present. TLC plates were run with crude methanol extract 
and 30% Pennah MeOH alone and on the same plate to better compare.  In the comparison there 
is one bright band visible under the long wavelength of UV light that shows up in both extracts. 
Another plate was run with four lanes of varying concentrations of 30% Pennah MeOH and was 
run in the solvent twice to try to further resolve the bands and possibly uncover bands hidden 
within areas already noted. These bands indicate groupings of compounds with similar mobility 
on the silica plate under the certain conditions, such as the solvent used to run them in the 
column. This was done to analyze how many major components may be present. This resulted in 
four distinct bands. The bands may indicate like components, but they do not necessarily indicate 
the presence of a single compound in each band. Each band indicates components of the extract 
that had similar mobility on the silica plate. Additional advanced analysis methods would need to 
be applied to the extract to gain a further understanding of the composition of 30% Pennah 
MeOH. 










 The research conducted in this study has established beyond doubt that Alchornea 
cordifolia possesses antiviral properties against HSV2 in Vero cells. The fraction of crude 
methanol extract that exhibited the highest plaque reduction was the 30% MeOH fraction. Based 
on varying time sensitive plaque assays, coupled with indirect immunofluorescence, the research 
suggests that the antiviral activity observed occurs during the events following attachment, 
possibly at the penetration step. These results do not allow for definitive answers surrounding the 
specific step the antiviral activity occurs. Due to time and resource limitations more research is 
necessary to determine the specific event that is disrupted. 
  Preliminary thin-layer chromatography suggests the presence of four main groupings of 
similar components based on mobility. Chemical class detection methods determined the 
presence of alkaloids, phenols, and terpenes, each class containing potential antivirals. 
Additional work is necessary to determine whether a single compound, or multiple compounds, 
are causing the antiviral activity observed. Further research concentrating on the identification, 
and consequent isolation, of active compounds found in Alchornea cordifolia is essential for the 
analysis of the mechanism of action this extract is exhibiting in Vero cells on HSV2. 
Identification of this compound and mode of action could result in useful medicinal development 
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